PH12022552743A1 - Feline antibody variants - Google Patents

Feline antibody variants

Info

Publication number
PH12022552743A1
PH12022552743A1 PH1/2022/552743A PH12022552743A PH12022552743A1 PH 12022552743 A1 PH12022552743 A1 PH 12022552743A1 PH 12022552743 A PH12022552743 A PH 12022552743A PH 12022552743 A1 PH12022552743 A1 PH 12022552743A1
Authority
PH
Philippines
Prior art keywords
antibody variants
feline antibody
feline
relates
variants
Prior art date
Application number
PH1/2022/552743A
Other languages
English (en)
Inventor
Lisa Marie Bergeron
Henry Luis Campos
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PH12022552743A1 publication Critical patent/PH12022552743A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2022/552743A 2020-04-17 2021-04-16 Feline antibody variants PH12022552743A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011491P 2020-04-17 2020-04-17
PCT/US2021/027839 WO2021212084A1 (en) 2020-04-17 2021-04-16 Feline antibody variants

Publications (1)

Publication Number Publication Date
PH12022552743A1 true PH12022552743A1 (en) 2024-03-25

Family

ID=75870744

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/552743A PH12022552743A1 (en) 2020-04-17 2021-04-16 Feline antibody variants

Country Status (17)

Country Link
US (2) US20240067730A1 (cg-RX-API-DMAC10.html)
EP (1) EP4136109A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023522030A (cg-RX-API-DMAC10.html)
KR (1) KR20230005158A (cg-RX-API-DMAC10.html)
CN (1) CN115667300A (cg-RX-API-DMAC10.html)
AU (1) AU2021257355A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022020631A2 (cg-RX-API-DMAC10.html)
CA (1) CA3176434A1 (cg-RX-API-DMAC10.html)
CL (2) CL2022002856A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022014684A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP22080858A (cg-RX-API-DMAC10.html)
IL (1) IL297290A (cg-RX-API-DMAC10.html)
MX (1) MX2022012793A (cg-RX-API-DMAC10.html)
PE (1) PE20230348A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022552743A1 (cg-RX-API-DMAC10.html)
TW (1) TW202204404A (cg-RX-API-DMAC10.html)
WO (1) WO2021212084A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
CN120005022A (zh) 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
JP7832123B2 (ja) 2020-05-11 2026-03-17 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
EP4166574A4 (en) * 2020-06-10 2025-01-15 Bica Therapeutics Inc. FUSION PROTEIN WITH ERYTHROPOIETIN POLYPEPTIDE
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
IL301414A (en) * 2020-09-29 2023-05-01 Zoetis Services Llc Feline antibody variants
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions
WO2026136223A1 (en) * 2024-12-19 2026-06-25 Zoetis Services Llc Compositions and methods for improving feline antibody functions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
KR101616758B1 (ko) * 2007-12-26 2016-04-29 젠코어 인코포레이티드 FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US10093731B2 (en) * 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
EP3866842A4 (en) * 2018-10-18 2022-07-13 Kindred Biosciences, Inc. FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE
WO2020116560A1 (ja) * 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のFc領域改変体

Also Published As

Publication number Publication date
EP4136109A1 (en) 2023-02-22
CA3176434A1 (en) 2021-10-21
US20240067730A1 (en) 2024-02-29
TW202204404A (zh) 2022-02-01
CL2023003376A1 (es) 2024-04-19
PE20230348A1 (es) 2023-03-02
CO2022014684A2 (es) 2022-11-08
CL2022002856A1 (es) 2023-06-02
BR112022020631A2 (pt) 2022-11-29
US20250026834A1 (en) 2025-01-23
MX2022012793A (es) 2022-11-07
ECSP22080858A (es) 2023-01-31
WO2021212084A1 (en) 2021-10-21
KR20230005158A (ko) 2023-01-09
CN115667300A (zh) 2023-01-31
IL297290A (en) 2022-12-01
AU2021257355A1 (en) 2022-11-03
JP2023522030A (ja) 2023-05-26

Similar Documents

Publication Publication Date Title
MX2022012793A (es) Variantes de anticuerpos felinos.
PH12022552742A1 (en) Canine antibody variants
MX2023008785A (es) Mutaciones en regiones constantes de anticuerpos caninos.
WO2022067233A3 (en) Canine antibody variants
MX2023003694A (es) Variantes de anticuerpos felinos.
MX2023003397A (es) Inmunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15.
WO2019224716A8 (en) Antibodies specific for gucy2c and uses thereof
PH12023550161A1 (en) Pharmaceutical composition and use thereof
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
JOP20220161A1 (ar) جسم مضاد لـ lilrb1 واستخداماته
MX2023005896A (es) Variantes de anticuerpos bovinos.
CO2023007829A2 (es) Mutaciones en regiones constantes de anticuerpos felinos
MX2022011077A (es) Variantes de transglutaminasa.
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
MX2023009549A (es) Compuestos y metodos para prolongar la vida media de biomoleculas.
MX2025001433A (es) Mutantes de anticuerpos bovinos
MX2025002522A (es) Mutantes de anticuerpos porcinos
CO2018006345A2 (es) Almidón estabilizado
MX2024013189A (es) Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
FR3035664B1 (fr) Utilisation de cysteine endoprotease pour diminuer le trouble de boissons
UA90682C2 (en) Variant fc regions